

---

# Contents

Foreword by Steven B. Karch .....	v
Preface .....	ix
Contributors .....	xxv
Product Identification Guide .....	following p.134

## PART I LEGAL/REGULATORY ASPECTS OF HERBAL PRODUCTS

Chapter 1: Legal/Regulatory Aspects of Herbal Products .....	3
<i>Melanie Johns Cupp</i>	

## PART II MONOGRAPHS

Chapter 1: Ma Huang and the <i>Ephedra</i> Alkaloids .....	11
<i>Steven B. Karch</i>	
1.1 Sources .....	11
1.2 History and Traditional Uses .....	11
1.3 Current Promoted Uses .....	12
1.4 Products Available .....	13
1.5 Pharmacology .....	15
1.5.1 Introduction .....	15
1.5.2 Pharmacologic Effects .....	16
1.5.3 Metabolism and Elimination .....	16
1.5.4 Workplace and Sports Drug Testing .....	17
1.6 Drug Interactions .....	17
1.7 Toxicology .....	18
1.7.1 Neurologic Disorders .....	18
1.7.2 Renal Disorders .....	20
1.7.3 Cardiovascular Diseases .....	21
1.7.4 Other Medical Problems and Effects .....	22

1.8	Postmortem Toxicology .....	23
1.9	Analytic Considerations .....	24
1.10	Methamphetamine Manufacture .....	24
1.11	Commission E Recommendations .....	25
Chapter 2: Kava .....		31
<i>Shawn Reeder and Melanie Johns Cupp</i>		
2.1	History and Traditional Uses .....	31
2.2	Current Promoted Uses .....	32
2.3	Products Available .....	32
2.4	Pharmacologic/Toxicologic Effects .....	32
2.4.1	Neurologic Effects .....	32
2.4.2	Dermatological Effects .....	35
2.4.3	Musculoskeletal Effects .....	36
2.4.4	Antimicrobial Activity .....	36
2.4.5	Hepatotoxicity .....	36
2.4.6	Antiplatelet Effects .....	36
2.5	Case Reports of Toxicity Due to Commercially Available Products .....	36
2.6	Toxicity Associated with Traditional Use by Native Peoples .....	37
2.7	Drug Interactions .....	38
2.8	Pharmacokinetics/Toxicokinetics .....	38
2.8.1	Absorption .....	38
2.8.2	Metabolism/Elimination .....	38
2.9	Analysis of Biofluids .....	38
2.10	Chemical Analysis .....	39
2.11	Regulatory Status .....	39
Chapter 3: <i>Ginkgo biloba</i> .....		43
<i>Forouzandeh Mahdavi and Melanie Johns Cupp</i>		
3.1	History and Traditional Use .....	43
3.2	Current Promoted Use .....	43
3.3	Products Available .....	43
3.4	Pharmacologic/Toxicologic Effects .....	44
3.4.1	Nervous System Effects .....	44
3.4.2	Cardiovascular Effects .....	46
3.4.3	Carcinogenicity/Mutagenicity/Teratogenicity .....	46
3.4.4	Endocrine Effects .....	47
3.5	Case Reports of Toxicity Due to Commercially Available Products .....	47
3.6	Drug Interactions .....	48
3.7	Pharmacokinetics/Toxicokinetics .....	48

3.7.1 Absorption .....	48
3.7.2 Distribution .....	49
3.7.3 Metabolism/Elimination .....	49
3.8 Chemical Analysis .....	49
3.9 Analysis of Biofluids .....	50
3.10 Regulatory Status .....	50
Chapter 4: Valerian .....	53
<i>Marlea Givens and Melanie Johns Cupp</i>	
4.1 History and/Traditional Uses .....	53
4.2 Current Promoted Uses .....	53
4.3 Products Available .....	54
4.4 Pharmacologic/Toxicologic Effects .....	54
4.4.1 Central Nervous System Effects .....	54
4.4.2 Musculoskeletal Effects .....	59
4.4.3 Reproduction .....	59
4.4.4 Cardiovascular Effects .....	60
4.4.5 Cytotoxicity .....	60
4.5 Case Reports of Toxicity Due to Commercially Available Products .....	61
4.6 Drug Interactions .....	63
4.7 Chemical Analysis .....	64
4.8 Regulatory Status .....	64
Chapter 5: St. John's Wort .....	67
<i>John T. Schwarz and Melanie Johns Cupp</i>	
5.1 History and Traditional Uses .....	67
5.2 Current Promoted Uses .....	67
5.3 Products Available .....	68
5.4 Pharmacologic/Toxicologic Effects .....	68
5.4.1 Neurological Effects .....	68
5.4.2 Antimicrobial Effects .....	70
5.4.3 Mutagenicity .....	70
5.4.4 Reproduction .....	70
5.5 Adverse Effects and Toxicity .....	70
5.6 Drug Interactions .....	72
5.7 Pharmacokinetics/Toxicokinetics .....	74
5.7.1 Absorption .....	74
5.7.2 Distribution .....	75
5.7.3 Metabolism/Elimination .....	75
5.8 Chemical Analysis .....	76
5.9 Analysis of Biofluids .....	76
5.10 Regulatory Status .....	76

Chapter 6: Chamomile .....	79
<i>Melanie Johns Cupp</i>	
6.1 History and Traditional Uses .....	79
6.2 Current Promoted Uses .....	79
6.3 Products Available .....	79
6.4 Pharmacologic/Toxicologic Effects .....	79
6.4.1 Neurologic Effects .....	79
6.4.2 Antineoplastic Effects .....	80
6.4.3 Anti-Inflammatory Activity .....	80
6.5 Case Reports of Toxicity Due to Commercially Available Products .....	80
6.6 Pharmacokinetics/Toxicokinetics .....	82
6.7 Analysis of Biofluids .....	82
6.8 Regulatory Status .....	82
Chapter 7: <i>Echinacea</i> .....	85
<i>Julie Davis and Melanie Johns Cupp</i>	
7.1 History and Traditional Uses .....	85
7.2 Current Promoted Uses .....	86
7.3 Products Available .....	86
7.4 Pharmacologic/Toxicologic Effects .....	86
7.4.1 Immunologic Effects .....	86
7.4.2 Antimicrobial/Antiviral Effects .....	87
7.4.3 Antineoplastic Activity .....	89
7.4.4 Wound-Healing .....	89
7.4.5 Anti-Inflammatory Effects .....	90
7.4.6 Mutagenicity/Carcinogenicity .....	90
7.4.7 Reproduction .....	90
7.5 Case Reports of Toxicity Due to Commercially Available Products .....	90
7.6 Chemical Analysis .....	91
7.7 Regulatory Status .....	91
Chapter 8: Feverfew .....	95
<i>Brian Schuller and Melanie Johns Cupp</i>	
8.1 History and Traditional Uses .....	95
8.2 Current Promoted Uses .....	95
8.3 Products Available .....	96
8.4 Pharmacology/Toxicology .....	97
8.4.1 Neurologic Effects .....	97
8.4.2 Anti-Inflammatory Effects .....	100
8.4.3 Mutagenicity/Carcinogenicity/Teratogenicity .....	101

8.5 Case Reports of Toxicity Due to Commercially Available Products .....	102
8.6 Drug Interactions .....	102
8.7 Chemical Analysis .....	103
8.8 Regulation .....	103
Chapter 9: Garlic .....	107
<i>James Allman and Melanie Johns Cupp</i>	
9.1 History and Traditional Uses .....	107
9.2 Current Promoted Uses .....	107
9.3 Products Available .....	107
9.4 Pharmacologic/Toxicologic Effects .....	109
9.4.1 Cardiovascular Effects .....	109
9.4.2 Gastrointestinal Effects .....	112
9.4.3 Antimicrobial Activity .....	112
9.4.4 Antineoplastic Activity .....	113
9.4.5 Immunostimulant Activity .....	114
9.5 Case Reports of Toxicity .....	115
9.6 Drug Interactions .....	118
9.7 Pharmacokinetics/Toxicokinetics .....	118
9.7.1 Absorption .....	118
9.7.2 Distribution .....	118
9.7.3 Metabolism/Elimination .....	118
9.8 Analysis of Biofluids .....	120
9.9 Regulatory Status .....	120
Chapter 10: Ginger .....	123
<i>Charity Metz and Melanie Johns Cupp</i>	
10.1 History and Traditional Uses .....	123
10.2 Current Promoted Uses .....	124
10.3 Products Available .....	124
10.4 Pharmacologic/Toxicologic Effects .....	125
10.4.1 Gastrointestinal Effects .....	125
10.4.2 Anti-Inflammatory Activity .....	126
10.4.3 Use in Migraine .....	127
10.4.4 Cardiovascular Effects .....	127
10.4.5 Mutagenicity .....	128
10.4.6 Reproduction .....	128
10.5 Case Reports of Toxicity Due to Commercially Available Products .....	128
10.6 Drug Interactions .....	129
10.7 Chemical Analysis .....	129
10.8 Regulatory Status .....	129

Chapter 11: Saw Palmetto .....	133
<i>Amy Meadows and Melanie Johns Cupp</i>	
11.1 History and Traditional Uses .....	133
11.2 Current Promoted Uses .....	133
11.3 Products Available .....	134
11.4 Pharmacologic/Toxicologic Effects .....	134
11.4.1 Immunologic Effects .....	134
11.4.2 Genitourinary/Endocrine Effects .....	134
11.4.3 Anti-Inflammatory Effects .....	136
11.5 Case Reports of Toxicity Due to Commercially Available Products .....	136
11.6 Pharmacokinetics/Toxicokinetics .....	137
11.6.1 Absorption .....	137
11.6.2 Distribution .....	137
11.6.3 Metabolism/Elimination .....	137
11.7 Analysis of Biofluids .....	137
11.8 Chemical Analysis .....	138
11.9 Regulatory Status .....	138
Chapter 12: <i>Panax</i> Ginseng .....	141
<i>Angela Morgan and Melanie Johns Cupp</i>	
12.1 History and Traditional Uses .....	141
12.2 Current Promoted Uses .....	142
12.3 Products Available .....	142
12.4 Pharmacologic/Toxicologic Effects .....	143
12.4.1 Endocrine Effects .....	143
12.4.2 Neurologic Effects .....	144
12.4.3 Cardiovascular Effects .....	144
12.4.4 Hematologic Effects .....	144
12.4.5 Immunologic Effects .....	145
12.4.6 Antineoplastic Effects .....	146
12.5 Case Reports of Toxicity Due to Commercially Available Products .....	145
12.6 Drug Interactions .....	147
12.7 Pharmacokinetics/Toxicokinetics .....	148
12.7.1 Absorption .....	148
12.7.2 Distribution .....	148
12.7.3 Metabolism/Elimination .....	149
12.8 Analysis of Biofluids .....	149
12.9 Chemical Analysis .....	150
12.10 Regulatory Status .....	150

Chapter 13: Cranberry .....	155
<i>Angela J. Lawson and Melanie Johns Cupp</i>	
13.1 History and Traditional Uses .....	155
13.2 Current Promoted Uses .....	155
13.3 Products Available .....	155
13.4 Pharmacologic/Toxicologic Effects .....	157
13.4.1 Antimicrobial Activity .....	157
13.4.2 Gastrointestinal Effects .....	158
13.4.3 Renal Effects .....	158
13.5 Chemical Analysis .....	159
13.6 Regulatory Status .....	159
Chapter 14: Borage .....	161
<i>Melanie Johns Cupp</i>	
14.1 History and Traditional Uses .....	161
14.2 Current Promoted Uses .....	162
14.3 Products Available .....	162
14.4 Pharmacologic/Toxicologic Effects .....	162
14.4.1 Anti-Inflammatory Effects .....	162
14.4.2 Dermatologic Effects .....	165
14.4.3 Respiratory Effects .....	166
14.4.4 Carcinogenicity .....	166
14.4.5 Hematologic Effects .....	166
14.4.6 Effects in Diabetic Neuropathy .....	166
14.4.7 Cardiovascular Effects .....	166
14.5 Case Reports of Toxicity .....	167
14.6 Pharmacokinetics/Toxicokinetics .....	167
14.7 Chemical Analysis .....	167
14.8 Regulatory Status .....	167
Chapter 15: Calamus .....	171
<i>Melanie Johns Cupp</i>	
15.1 History and Traditional Uses .....	171
15.2 Current Promoted Uses .....	172
15.3 Products Available .....	172
15.4 Pharmacologic/Toxicologic Effects .....	172
15.4.1 Carcinogenicity .....	172
15.4.2 Mutagenicity/Genotoxicity .....	172
15.4.3 Antimicrobial Activity .....	172
15.4.4 Central Nervous System Effects .....	172
15.4.5 Musculoskeletal Effects .....	173

15.4.6 Cardiovascular Effects .....	173
15.4.7 LD <sub>50</sub> .....	174
15.4.8 Reproductive Effects .....	174
15.4.9 Local Anesthetic Effects .....	174
15.5 Case Reports of Toxicity .....	174
15.6 Chemical Analysis .....	174
15.7 Regulatory Status .....	174
Chapter 16: Chaparral .....	177
<i>Kim Melgarejo and Melanie Johns Cupp</i>	
16.1 History and Traditional Uses .....	177
16.2 Current Promoted Uses .....	178
16.3 Products Available .....	178
16.4 Pharmacologic/Toxicologic Effects .....	178
16.4.1 Antineoplastic Activity .....	178
16.4.2 Hepatotoxicity .....	180
16.4.3 Effects on the Arachidonic Acid Cascade .....	180
16.4.4 Nephrotoxicity .....	181
16.4.5 Carcinogenicity .....	182
16.4.6 Dermatologic Effects .....	182
16.4.7 Antihyperglycemic Effects .....	182
16.5 Case Reports of Toxicity Due to Commercially Available Products .....	182
16.6 Drug Interactions .....	187
16.7 Pharmacokinetics .....	187
16.8 Chemical Analysis/Analysis of Biofluids .....	188
16.9 Regulatory Status .....	188
Chapter 17: Coltsfoot .....	191
<i>Amanda Dailey and Melanie Johns Cupp</i>	
17.1 History and Traditional Uses .....	191
17.2 Current Promoted Uses .....	191
17.3 Products Available .....	192
17.4 Pharmacologic/Toxicologic Effects .....	192
17.4.1 Respiratory Effects .....	192
17.4.2 Cardiovascular Effects .....	193
17.4.3 Antimicrobial Effects .....	193
17.4.4 Hepatotoxicity .....	193
17.4.5 Carcinogenicity/Genotoxicity .....	194
17.5 Case Reports of Toxicity Due to Commercially Available Products .....	195
17.6 LD <sub>50</sub> .....	198
17.7 Pharmacokinetics/Toxicokinetics .....	198



17.7.1 Absorption .....	198
17.7.2 Distribution .....	198
17.7.3 Metabolism/Elimination .....	198
17.8 Analysis of Biofluids/Chemical Analysis .....	199
17.9 Regulatory Status .....	200
Chapter 18: Comfrey .....	203
<i>David Burch and Melanie Johns Cupp</i>	
18.1 History and Traditional Uses .....	203
18.2 Current Promoted Uses .....	204
18.3 Products Available .....	204
18.4 Pharmacologic/Toxicologic Effects .....	204
18.4.1 Gastrointestinal Effects .....	205
18.4.2 Hepatotoxicity .....	205
18.4.3 Carcinogenicity/Mutagenicity .....	206
18.4.4 LD <sub>50</sub> .....	207
18.5 Case Reports of Toxicity Due to Commercially Available Products .....	208
18.6 Drug Interactions .....	210
18.7 Pharmacokinetics/Toxicokinetics .....	210
18.7.1 Absorption .....	210
18.7.2 Distribution .....	211
18.7.3 Metabolism/Elimination .....	211
18.8 Analysis of Biofluids .....	211
18.9 Chemical Analysis .....	212
18.10 Regulatory Status .....	212
Chapter 19: Scullcap .....	215
<i>Jennifer Schumacher and Melanie Johns Cupp</i>	
19.1 History and Traditional Uses .....	215
19.2 Current Promoted Uses .....	216
19.3 Products Available .....	216
19.4 Pharmacologic/Toxicologic Effects .....	216
19.4.1 Antispasmodic Effects .....	216
19.4.2 Hepatotoxicity .....	216
19.4.3 Cardiovascular Effects .....	216
19.4.4 Antimicrobial Activity .....	217
19.4.5 Anti-Inflammatory Activity .....	217
19.4.6 Chemotherapeutic Activity .....	218
19.5 Case Reports of Toxicity Due to Commercially Available Products .....	218
19.6 Chemical Analysis .....	220
19.7 Regulatory Status .....	220

Chapter 20: Licorice .....	223
<i>Michael Newton and Melanie Johns Cupp</i>	
20.1 History and Traditional Uses .....	223
20.2 Current and Promoted Uses .....	223
20.3 Products Available .....	224
20.4 Pharmacologic/Toxicologic Effects .....	224
20.4.1 Respiratory Effects .....	224
20.4.2 Anti-Inflammatory Effects .....	224
20.4.3 Adrenocorticotropic Effects .....	225
20.4.4 Gastrointestinal Effects .....	226
20.4.5 Antimicrobial Activity .....	226
20.5 Case Reports of Toxicity Due to Commercially Available Products .....	227
20.6 Pharmacokinetics/Toxicokinetics .....	231
20.6.1 Absorption .....	231
20.6.2 Distribution .....	231
20.6.3 Metabolism/Elimination .....	231
20.6.4 Analysis of Biofluids .....	232
20.7 Regulatory Status .....	232
Chapter 21: Pokeweed .....	237
<i>A. Heather Knight-Trent and Melanie Johns Cupp</i>	
21.1 History and Traditional Uses .....	237
21.2 Products Available .....	238
21.3 Pharmacologic/Toxicologic Effects .....	238
21.3.1 Antimicrobial Activity and Antineoplastic Activity .....	238
21.3.2 Anti-Inflammatory Activity .....	238
21.3.3 Cardiovascular Effects .....	238
21.3.4 Musculoskeletal Effects .....	239
21.3.5 Gastrointestinal Effects .....	239
21.3.6 Respiratory Effects .....	239
21.3.7 Neurologic Effects .....	239
21.3.8 Hematologic Effects .....	239
21.4 Case Reports of Toxicity .....	239
21.5 Pharmacokinetics/Toxicokinetics .....	242
21.6 Chemical Analysis .....	242
21.7 Regulatory Status .....	242
Chapter 22: <i>Sassafras</i> .....	245
<i>David Hutson and Melanie Johns Cupp</i>	
22.1 History and Traditional Uses .....	245
22.2 Current Uses .....	246
22.3 Pharmacologic/Toxicologic Effects .....	246

22.3.1 Anti-Inflammatory Activity .....	246
22.3.2 Antineoplastic Activity .....	246
22.3.3 Carcinogenicity .....	246
22.3.4 Antimicrobial Activity .....	247
22.4 Case Reports of Toxicity .....	248
22.5 Pharmacokinetics/Toxicokinetics .....	249
22.5.1 Absorption .....	249
22.5.2 Distribution .....	249
22.5.3 Metabolism/Elimination .....	249
22.6 Drug and food Interactions .....	250
22.7 Analysis of Biofluids .....	250
22.8 Regulatory Status .....	251
Chapter 23: Hawthorn .....	253
<i>Jennifer Annon and Melanie Johns Cupp</i>	
23.1 History and Traditional Uses .....	253
23.2 Current Promoted Uses .....	254
23.3 Products Available .....	254
23.4 Pharmacologic/Toxicologic Effects .....	254
23.4.1 Cardiovascular Effects .....	254
23.4.2 Neurologic Effects .....	256
23.4.3 LD <sub>50</sub> .....	256
23.4.4 Teratogenicity/Mutagenicity/Carcinogenicity .....	256
23.5 Case Reports of Toxicity Due to Commercially Available Products .....	256
23.6 Pharmacokinetics/Toxicokinetics .....	257
23.7 Chemical Analysis .....	257
23.8 Regulatory Status .....	257
Chapter 24: <i>Aloe</i> .....	259
<i>Tara Dalton and Melanie Johns Cupp</i>	
24.1 History and Traditional Uses .....	259
24.2 Current Promoted Uses .....	260
24.3 Products Available .....	260
24.4 Pharmacologic/Toxicologic Effects .....	261
24.4.1 Gastrointestinal Effects .....	261
24.4.2 Carcinogenicity/Genotoxicity .....	262
24.4.3 Hematopoietic Activity .....	262
24.4.4 Antimicrobial Activity .....	263
24.4.5 Antineoplastic Activity .....	264
24.4.6 Anti-Inflammatory and Wound Healing Activity .....	264
24.5 Case Reports of Toxicity Due to Commercially Available Products .....	266

24.6	Potential Drug Interactions .....	267
24.7	Pharmacokinetics/Toxicokinetics .....	267
24.7.1	Absorption .....	267
24.7.2	Distribution .....	268
24.7.3	Metabolism/Elimination .....	268
24.8	Analysis of Biofluids .....	268
24.9	Regulatory Status .....	269
Chapter 25:	Senna .....	273
	<i>Melanie Johns Cupp</i>	
25.1	History and Chemistry .....	273
25.2	Current Promoted Uses .....	274
25.3	Products Available .....	274
25.4	Pharmacologic/Toxicologic Effects .....	274
25.4.1	Carcinogenicity/Mutagenicity/Genotoxicity .....	274
25.4.2	Gastrointestinal Effects .....	276
25.4.3	Laxative Abuse .....	278
25.5	Pharmacokinetics/Toxicokinetics .....	278
25.5.1	Absorption .....	278
25.5.2	Distribution .....	279
25.5.3	Metabolism/Elimination .....	279
25.6	Chemical Analysis .....	279
25.7	Analysis of Biofluids .....	279
25.8	Regulatory Status .....	280
Chapter 26:	Cascara Sagrada .....	283
	<i>Amy Renner and Melanie Johns Cupp</i>	
26.1	History and Traditional Uses .....	283
26.2	Current Promoted Uses .....	283
26.3	Products Available .....	283
26.4	Pharmacologic/Toxicologic Effects .....	284
26.4.1	Gastrointestinal Effects .....	284
26.4.2	Nutritional/Metabolic Effects .....	284
26.4.3	Carcinogenicity/Mutagenicity/Genotoxicity .....	284
26.5	Case Reports of Toxicity Due to Commercially Available Products .....	285
26.6	Drug Interactions .....	285
26.7	Pharmacokinetics/Toxicokinetics .....	285
26.8	Analysis of Biofluids .....	286
26.9	Chemical Analysis .....	286
26.10	Regulatory Status .....	286

Chapter 27: Dong Quai .....	289
<b><i>Rayna De Rosa and Melanie Johns Cupp</i></b>	
27.1 History and Traditional Uses .....	289
27.2 Current Promoted Uses .....	289
27.3 Products Available .....	289
27.4 Pharmacologic/Toxicologic Effects .....	290
27.4.1 Cardiovascular Effects .....	290
27.4.2 Neurologic Effects .....	290
27.4.3 Musculoskeletal Effects .....	290
27.4.4 Immunologic Effects/Antineoplastic Activity/Antimicrobial Activity .....	291
27.4.5 Anit-Inflammatory Activity .....	291
27.4.6 Dermatological Effects .....	291
27.4.7 Carcinogenicity .....	291
27.4.8 Estrogenic Effects .....	292
27.4.9 Gastrointestinal Effects .....	292
27.5 Drug Interactions .....	292
27.6 Chemical Analysis .....	293
27.7 Regulatory Status .....	293
Chapter 28: Cat's Claw .....	295
<b><i>Melissa Dawn Bostic and Melanie Johns Cupp</i></b>	
28.1 History and Traditional Uses .....	295
28.2 Current Promoted Uses .....	295
28.3 Products Available .....	296
28.4 Pharmacologic/Toxicologic Effects .....	296
28.4.1 Antiviral Effects .....	296
28.4.2 Antineoplastic Activity .....	296
28.4.3 Antimutagenic Activity .....	296
28.4.4 Cytotoxicity .....	297
28.5 Case Reports of Toxicity Due to Commercially Available Products .....	297
28.6 Regulatory Status .....	297
<b>PART III SUMMARY OF TOXICITIES AND DRUG INTERACTIONS</b>	
Chapter 1: Summary of Toxicities and Drug Interactions .....	301
<b><i>Melanie Johns Cupp</i></b>	
Index .....	303



<http://www.springer.com/978-0-89603-791-5>

Toxicology and Clinical Pharmacology of Herbal  
Products

Cupp, M.J.

2000, XXVI, 325 p., Hardcover

ISBN: 978-0-89603-791-5

A product of Humana Press